Advances in molecular understanding of cancer continue to drive the development of increasingly selective and effective treatments. This session focuses on anticancer drug discovery, targeted therapies, small molecules, antibody-based approaches, antibody-drug conjugates, bispecific antibodies, novel delivery systems, and mechanisms of treatment resistance.
Abstract Scope and Participation
Abstracts are invited on drug discovery, targeted therapy, small-molecule inhibitors, monoclonal antibodies, ADCs, bispecific antibodies, drug delivery, nanomedicine, pharmacology, resistance mechanisms, and therapeutic optimization. Academic researchers, clinicians, pharmacologists, biotechnology scientists, and pharmaceutical professionals are encouraged to participate.